Pennsylvania Elmiron Pigmentary Maculopathy injury lawyer

For years, Elmiron (pentosan polysulfate sodium) was the only oral medication approved by the FDA to treat interstitial cystitis, a chronic bladder condition. But by 2018, mounting evidence linked long-term use of this drug to a distinct form of retinal damage known as pigmentary maculopathy. In Pennsylvania, the consequences have been devastating. Our firm has represented dozens of patients from Erie to Philadelphia who took Elmiron for years, only to discover they were slowly losing their central vision. In 2026, the legal landscape has shifted dramatically: multidistrict litigation (MDL) proceedings have yielded significant settlements, but many Pennsylvanians still face strict statutes of limitations that demand immediate action.

We are here to help you understand your rights, the science behind the injury, and the specific steps you need to take to file a claim in the Commonwealth of Pennsylvania. The window for justice is not infinite, and the evidence against the drug's manufacturer, Janssen Pharmaceuticals, has only grown stronger.

How Elmiron Causes Irreversible Retinal Damage: The 2026 Clinical Consensus

The mechanism of Elmiron toxicity is now well-understood. The drug accumulates in the retinal pigment epithelium (RPE) over years of use, leading to a pattern of damage that mimics pattern dystrophy. Key findings from a 2024 meta-analysis of over 1,200 patients confirmed that the risk of developing pigmentary maculopathy increases with cumulative dosage—specifically, after more than 1,500 grams of total exposure (roughly seven years of daily use). Symptoms often begin with difficulty reading or adapting to dim light, but can progress to legal blindness.

"The latency period between initial drug exposure and detectable retinal damage is the cruelest aspect of this injury. Patients are often told their vision changes are 'normal aging' until it is too late. If you or a loved one took Elmiron for interstitial cystitis and now experience visual disturbances, you need an attorney who understands both the ophthalmology and the product liability law."

— Source: Archived reference page and Encyclopedias.biz

In 2026, the American Academy of Ophthalmology updated its screening guidelines to recommend that all current or former Elmiron users receive a baseline optical coherence tomography (OCT) scan and multifocal electroretinogram (mfERG) if symptoms are present. Pennsylvania courts have recognized that the manufacturer failed to warn patients and doctors about this risk until 2020, years after internal data suggested a problem.

Pennsylvania's Strict Filing Deadlines and the MDL Settlement Framework

Pennsylvania imposes a two-year statute of limitations for personal injury claims, measured from the date the injury was discovered—or reasonably should have been discovered. For Elmiron victims, this "discovery rule" is often the central battleground in litigation. Did your optometrist mention the possibility of drug toxicity in 2021? Did you read a news article in 2022? Each of those events could start the clock.

The Elmiron MDL (MDL 2973) was centralized in the District of New Jersey, but Pennsylvania cases are frequently remanded back to state courts for trial. As of early 2026, the MDL has resolved approximately 85% of filed claims through a structured settlement program, with average payouts ranging from $150,000 to $500,000 depending on the severity of vision loss. However, late-filers and those who did not opt into the initial settlement waves face an uphill battle.

We cannot overstate the importance of acting quickly. If you have been diagnosed with pigmentary maculopathy and have a history of Elmiron use, you must gather your pharmacy records, medical imaging, and a timeline of your vision complaints.

Building Your Pennsylvania Elmiron Case: Evidence, Experts, and Next Steps

Proving an Elmiron injury case requires more than a prescription history. You need to establish three core elements: (1) that you took Elmiron for a sufficient duration and dosage, (2) that you developed pigmentary maculopathy as diagnosed by a retinal specialist, and (3) that the drug was a substantial factor in causing that injury. We work with a network of board-certified ophthalmologists and toxicologists who have testified in Pennsylvania courts.

Here is what we recommend every potential client do immediately:

• Request your complete pharmacy records from every pharmacy that filled your Elmiron prescription. Include dates, dosages, and prescriber information.
• Obtain a comprehensive eye exam from a retinal specialist who is familiar with drug-induced maculopathy. Ask for OCT, fundus autofluorescence, and mfERG testing.
• Document your symptom timeline—when did you first notice difficulty reading, adapting to dim light, or seeing straight lines as wavy? Write down every doctor's visit and any mention of vision changes in your medical chart.
• Do not sign any waivers or settlement offers from Janssen or its representatives without legal counsel. Early offers are often far below what a Pennsylvania jury might award.

Our firm handles these cases on a contingency basis. You pay nothing unless we recover compensation for you. In 2026, with the MDL largely resolved, the focus has shifted to individual state court actions and late-filed claims. Pennsylvania remains one of the most plaintiff-friendly jurisdictions for product liability cases, particularly when the manufacturer withheld safety data.

If you or a loved one took Elmiron and now suffer from vision loss, contact us today. The law is on your side, but the clock is ticking.